Novo Nordisk (CPSE:NOVO B) Could Be 12% Overvalued As Wegovy Access Expands

Novo Nordisk (CPSE:NOVO B) is back in the spotlight after the Medicare GLP-1 Bridge expanded access to Wegovy in the US, while fresh semaglutide data and delivery partnerships continue to focus attention on the company’s obesity franchise.

See our latest analysis for Novo Nordisk.

The Medicare GLP-1 Bridge, fresh Wegovy approvals, and the Vivani implant evaluation have coincided with a 30-day share price return of 13.83% and a 90-day share price return of 33.91% for Novo Nordisk. Over the same period, the 1-year total shareholder return declined 23.19%, suggesting momentum has recently picked up after a weaker stretch for longer term holders.

If Novo Nordisk’s obesity push has your attention, this is also a good moment to see what else is moving in weight loss and metabolic health by checking the 130 healthcare AI stocks

After a sharp rebound and with Novo Nordisk trading slightly above the average analyst target but at a sizeable discount to one popular fair value estimate, is the recent caution around the stock still warranted?

Most Popular Narrative: 12.3% Overvalued

The latest narrative fair value for Novo Nordisk of DKK287 sits below the last close at DKK322.25, framing a clear valuation gap that investors are watching closely.

Novo Nordisk’s business model is straightforward. It develops hormone-based therapies, protects them with patents, manufactures them at scale, and sells them at high margins into reimbursed healthcare systems. In obesity, GLP-1 drugs such as Wegovy transformed the company into a perceived structural growth leader. The stock was priced for durable dominance. The pullback reflects emerging limits to that assumption.

Read the complete narrative.

Want to see what sits behind that DKK287 figure? The narrative leans heavily on capacity ceilings, payer access, and a profit multiple that looks far more restrained than past hype.

Result: Fair Value of DKK287 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, if Medicare coverage broadens faster than expected, or if Novo Nordisk executes smoothly on manufacturing capacity, that DKK287 narrative anchor could come under pressure.

Find out about the key risks to this Novo Nordisk narrative.

Another View: Novo Nordisk Through The Earnings Multiple

The user narrative pins Novo Nordisk as 12.3% overvalued at DKK287, yet the stock trades on a P/E of 11.7x while peers sit on 24.9x and the fair ratio is 22.8x. That sizeable gap cuts the other way, so which story do you trust more: the narrative or the multiple?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mixed signals around Novo Nordisk leave you unsure, move quickly from headline takes to hard data and weigh both sides of the story with the 3 key rewards and 4 important warning signs

Looking for more investment ideas beyond Novo Nordisk?

If Novo Nordisk has sharpened your focus, do not stop here. Broaden your watchlist with other stocks that fit clear, evidence based filters on Simply Wall Street.

• Target companies that combine quality and value by reviewing the 211 high quality undervalued stocks before they are crowded with attention.
• Prioritise stability first and check the 296 resilient stocks with low risk scores to focus on businesses with more resilient profiles.
• Hunt for tomorrow’s potential standouts early by scanning the screener containing 499 high quality undiscovered gems while they are still off most investors’ radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com